Pre-made Amatuximab benchmark antibody ( Whole mAb, anti-MSLN therapeutic antibody, Anti-MPF/SMRP Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-020

Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-020-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Amatuximab biosimilar, Whole mAb, Anti-MSLN Antibody: Anti-MPF/SMRP therapeutic antibody
INN Name Amatuximab
TargetMSLN
FormatWhole mAb
DerivationChimeric (Mouse/Human)
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusActive
100% SI StructureNone
99% SI Structure4f33:BA:DC:FE:HG/4f3f:BA
95-98% SI StructureNone
Year Proposed2010
Year Recommended2011
CompaniesEisai Co Ltd;Morphotek;National Cancer Institute (USA)
Conditions Approvedna
Conditions ActiveMesothelioma
Conditions DiscontinuedPancreatic cancer;Solid tumours
Development Techna